Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Patients with relapsed/refractory (R/R) AML with mutation ( ) have a dismal prognosis. offers a target for therapy in these patients. Gilteritinib (gilter) and quizartinib (quizar) have demonstrated efficacy as single agents in two phase 3 clinical trials. We retrospectively analyzed the characteris...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2024-12, Vol.16 (23), p.4028
Hauptverfasser:	Vives, Susana, Quintela, David, Morgades, Mireia, Cano-Ferri, Isabel, Serrano, Alfons, Acuña-Cruz, Evelyn, Cervera, Marta, Díaz-Beyá, Marina, Vidriales, Belén, Raposo-Puglia, José Ángel, Arnan, Montserrat, Garrido, Ana, Balerdi, Amaia, Cabello, Ana Isabel, Herrera-Puente, Pilar, Serrano, Josefina, Coll, Rosa, Tormo, Mar, López-Marín, Javier, García-Ávila, Sara, Casado, María Soledad, Padilla, Irene, Rodríguez-Macías, Gabriela, Calbacho, María, Puchol, Ana, Hernández, Agustín, Torres, Melissa, Costilla, Lissette, Colorado, Maria Mercedes, Martínez-Cuadrón, David, Esteve, Jordi, Montesinos, Pau
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Bone marrow Cancer Chemotherapy Clinical trials FLT3 gene Gene mutations Genetic aspects Health aspects Kinases Laboratories Leukemia Medical prognosis Mutation Patients Remission (Medicine) Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!